MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD DisclosureITEM 7.01
REGULATION FD DISCLOSURE
MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD Disclosure
On February 28, 2018, MabVax Therapeutics Holdings, Inc. (the “Company”) issued a press release that reported positive safety results from the initial cohort of the Phase 1 clinical trial evaluating the Company’s new human antibody-based radioimmunotherapy (“RIT”) product designated as MVT-1075 for the treatment of pancreatic, colon and lung cancers. The press release is attached hereto as Exhibit 99.1.
The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
|
ITEM 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS |
(d)Exhibits.
The exhibit listed in the following Exhibit Index is furnished with this Current Report on Form 8-K.
|
Exhibit No. |
Description |
|
Press release issued February 28, 2018 |
MABVAX THERAPEUTICS HOLDINGS, INC. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE Ex 99-1 Exhibit 99.1 MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic,…To view the full exhibit click here
